Sentinel Capital Partners Acquires TTG Imaging Solutions

Growth Platform in Specialized Medical Imaging Services

Sentinel Capital Partners, a private equity firm that invests in promising mid-market companies, today announced its acquisition of TTG Imaging Solutions, a leading national provider of nuclear medicine and molecular imaging solutions. The terms of the deal were not disclosed.

Headquartered in Pittsburgh, Pennsylvania, TTG offers end-to-end solutions for cardiology and oncology customers that use diagnostic imaging equipment. Through a nationwide network of field service engineers, TTG offers equipment, maintenance and repair services, clinical staffing, and radiopharmaceutical products. TTG operates three equipment repair centers and three radiopharmacies that serve customers across 46 states. Founded in 2004, TTG has completed nine acquisitions that have expanded its geographic coverage and added new technical capabilities.

“Since its founding, TTG has built a reputation of providing best-in-class services that allow physicians, imaging centers, and hospitals to offer top-quality patient care,” said Paul Murphy, a Sentinel partner. “The TTG team has developed an impressive growth playbook and we are thrilled to provide them the capital and support to significantly expand the business. We look forward to working with TTG’s talented team as they enter their next chapter of growth.”

“We are excited to partner with Sentinel as TTG continues to expand within the large and growing imaging services market,” said CEO Matthew Mastarone. “Our goal was to find a partner to provide capital for continuing growth over the next several years, and to support our mission of providing our customers and their patients with the highest quality of service. Sentinel is a perfect fit for what we are aiming to accomplish.”

In addition to its extensive experience in healthcare services, Sentinel has significant industry expertise in third-party equipment sales and service in a variety of end-markets. Such investments include New Era Technology (IT solutions), Mobile Communications America (networked communications), and UBEO (document management).

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”